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Abstract 16 
Sirtuin 3 (Sirt3) has a promising role in cancer tumorigenesis and treatment, but there have been 17 
controversies about its role as oncogene or tumor suppressor in different types of cancer. 18 
Changes in its expression are associated with the excessive production of reactive oxygen 19 
species (ROS), thus contributing to mitochondrial dysfunction and age-related pathologies. 20 
Hyperoxic treatment (i.e. generator of ROS) was shown to support some tumorigenic 21 
properties, but finally suppresses growth of certain mammary carcinoma cells. Due to strikingly 22 
reduced Sirt3 level in many breast cancer cell lines, we aimed at deciphering the effect of de 23 
novo Sirt3 expression upon hyperoxic treatment in the human MCF-7 breast cancer cells. De 24 
novo expression of Sirt3 decreased metabolic activity and cellular growth of MCF-7 cells, 25 
reduced expression of pro-angiogenic and epithelial mesenchymal transition genes, induced 26 
metabolic switch from glycolysis to oxidative phosphorylation, and decreased abundance of 27 
senescent cells. These effects were enhanced upon hyperoxic treatment: induction of DNA 28 
damage and upregulation of p53, with increase of ROS levels followed by mitochondrial and 29 
antioxidant dysfunction, resulted in additional reduction of metabolic activity and inhibition of 30 
cellular growth and survival. The mitigation of tumorigenic properties and enhancement of the 31 
susceptibility of the MCF-7 breast cancer cells to the hyperoxic treatment upon de novo Sirt3 32 
expression, indicates that these factors, individually and in combination, should be further 33 
explored in vitro and particularly in vivo, as an adjuvant tumor therapy in breast cancer 34 
malignancies.  35 
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Introduction 38 
Sirtuin 3 (Sirt3) is a major mitochondrial NAD+-dependent deacetylase that plays critical role 39 
in activation of mitochondrial proteins involved in energy metabolism, ATP production and 40 
mitochondrial biogenesis (1). Longer, enzymatically inactive form of Sirt3 (44 kDa) is imported 41 
into mitochondria by the N-terminal mitochondrial localization sequence (MLS). Following the 42 
import, the MLS is proteolytically cleaved, resulting in catalytically active, short form of Sirt3 43 
(28 kDa) which is able to deacetylate target mitochondrial proteins (2). Sirt3 is the only member 44 
of sirtuin family that is linked with prolonged lifespan. Therefore, the control of enzymes 45 
involved in energy metabolism by Sirt3 is in accordance with the overall protection against 46 
pathological conditions and aging itself (3). However, there have been controversies about the 47 
role of Sirt3 in different types of cancer (4). 48 
Cancer cells exhibit prominent genetic, metabolic and bioenergetic differences when compared 49 
to normal cells: high rate of glycolysis, lactate production along with the absence of respiration, 50 
despite the presence of oxygen thus characterizing the phenomenon known as Warburg effect 51 
(5). Because of rapid proliferation, cancer cells quickly exhaust nutrients and oxygen supply, 52 
making tumor microenvironment hypoxic. Under hypoxia, tumor's surroundings become acidic 53 
as a result of increased lactate production and excretion, thus contributing to the malignant 54 
phenotype of the cancer (6). However, although tumor cells often live in hypoxic conditions 55 
due to metabolic and structural abnormalities, their angiogenesis, growth and survival depend 56 
upon the sufficient supply of oxygen and nutrients. Therefore, one would expect that enhanced 57 
oxygenation (hyperoxia) would exert a tumor-promoting effect. On the other hand, several 58 
reports demonstrate growth suppression of mammary carcinoma cells upon hyperoxic treatment 59 
(7), thus pointing out the therapeutic effect of hyperoxia on tumor growth and proliferation.  60 
The excessive production of reactive oxygen species (ROS) leads to oxidative stress, a crucial 61 
event that contributes to mitochondrial dysfunction and age-related pathologies (8). It has been 62 
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shown that irregular ROS production or scavenging is associated with changes in Sirt3 63 
expression (9). Recent data report the association between Sirt3 levels and cancer progression, 64 
with either oncogenic or tumor-suppressive role of Sirt3 in cancer (4, 10). Several studies 65 
described a prosurvival role of Sirt3 in certain cancer cell lines, thus supporting its oncogenic 66 
role in cancer, although the exact mechanism by which Sirt3 exerts its action is not fully 67 
understood. On the other hand, Sirt3 is recognized as a fidelity protein that repairs cellular 68 
molecules, and it is involved in metabolic reprogramming of some breast cancer cell lines 69 
towards oxidative phosphorylation (OXPHOS) (11), and as such may be considered as a tumor 70 
suppressor gene. Therefore, the loss of function of Sirt3 may contribute to a more aggressive 71 
phenotype in some types of cancers (1).  72 
Although hyperoxic treatment is clinically important for treatment of hypoxia, it is known that 73 
exposure to the increased oxygen concentrations causes impaired energy metabolism that 74 
results in dysfunction of normal cells (12). Since hypoxia is a hallmark of various tumors, we 75 
hypothesized that hyperoxia would have negative impact on cancer cells, thus providing 76 
therapeutic strategy against their tumorigenic properties. In addition, considering tumor 77 
suppressive role of Sirt3 in cancerogenesis, we hypothesized that Sirt3 expression would also 78 
negatively impact the cancerous cells, especially in combination with hyperoxic treatment.  79 
Breast cancer is the most frequent cancer among women, and ranks as the fifth cause of cancer 80 
death worldwide (13). Sirtuin family of genes shows differential expressions in breast cancer 81 
cells, which is often different from the expression in the breast cancer tissues (14). Since breast 82 
cancer cells have strikingly reduced Sirt3 level, and even 20% of them have almost no 83 
detectable Sirt3 protein (15), we wanted to examine the effect of de novo Sirt3 expression upon 84 
hyperoxic treatment in human MCF-7 breast cancer cells model. This setting of de novo 85 
expression is advantageous because it is the only changing factor in the control and transfected 86 
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cells under the same treatment, thus providing a model which avoids any possible phenotypic 87 
distinctions in the cells caused by other factors. 88 
Therefore, in this study we have developed human MCF-7 breast cancer cells transfectants 89 
expressing the Sirt3 protein in order to test its potential in affecting the response of these cells 90 
upon the hyperoxic treatment, i.e. to decipher whether it sensitizes or makes these cancer cells 91 
more resistant to oxidative stress. 92 
Materials and methods 93 
Cell lines, plasmids and transfection 94 
MCF-7 cell line, obtained from the ECACC (Cat.No. 86012803, Public Health England), was 95 
grown in Dulbecco's Modified Eagle Medium with high glucose (DMEM, Sigma Aldrich, St. 96 
Louis, MO, USA) with 10% fetal bovine serum (FBS, Invitrogen/Life Technologies, Carlsbad, 97 
CA, USA), 2mM L-glutamine (Sigma Aldrich, St. Louis, MO, USA), 1% nonessential amino 98 
acids and antibiotic/antimycotic solution GA-1000 (Lonza, USA), at 37°C with 5% CO2 in a 99 
humidified atmosphere. pcDNA3.1+ plasmid with Flag-tagged Sirt3 (Cat.No. 13814), 100 
purchased from Addgene, USA (16), was amplified in E.coli strain dH5α and purified with 101 
PureYieldTM Plasmid Midiprep System (Promega, USA) according to the manufacturer's 102 
protocol. pcDNA3.1+ (given by courtesy of dr.sc. Grbeša) was used as a control plasmid. The 103 
MCF-7 cells were transfected with the Flag-tagged Sirt3 or empty pcDNA3.1+ plasmid using 104 
Lipofectamine 2000 (ThermoFisher Scientific, USA), according to the manufacturer's protocol. 105 
Briefly, 1.5 x 105 cells were seeded on 24-well plate in growth medium and 24 h later 106 
transfected and incubated for additional 24 h. The cells were then split into selective growth 107 
medium containing 200 µg/ml G418 antibiotic (Sigma Aldrich, St. Louis, MO, USA). Colonies 108 
of stable Sirt3 transfectants were picked, expanded in the growth media containing G418 109 
antibiotic, and cryogenically stored at −80°C. 110 
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Normoxic and hyperoxic conditions 111 
Cells were exposed to hyperoxia (95% O2) for 44 h in a gas-tight modular incubator chamber 112 
(StemCellTM Technology Inc., Canada) at 37°C in order to establish hyperoxia-treated groups, 113 
while the normoxic groups were exposed to normal growth conditions. 114 
Immunofluorescence and confocal microscopy 115 
Immunofluorescence analysis was performed as described previously (17). Briefly, cells were 116 
labelled with 200 nM MitoTracker Deep Red (ThermoFisher Scientific, USA), fixed with 2% 117 
paraformaldehyde, incubated with anti-Sirt3 primary polyclonal antibody (dilution 1:100, Santa 118 
Cruz, USA), followed by FITC-labeled Goat anti-Mouse IgG secondary antibody (dilution 119 
1:100, Proteintech, USA). DAPI (4,6-diamidino-2-fenilindol, Sigma Aldrich, St. Louis, MO, 120 
USA) was used for nuclear staining. Confocal imaging was performed by sequential scanning 121 
using Leica TCS SP8 X laser scanning microscope, equipped with a HC PL APO CS2 63×/1.40 122 
oil immersion objective and a white light laser (Leica Microsystems, Germany). The excitation 123 
wavelengths and emission detection ranges used were 405 nm and 420-477 nm for DAPI, 490 124 
nm and 500-600 nm for FITC, 644 nm and 665-780 nm for MitoTracker Deep Red. 125 
RNA isolation, reverse transcription and qPCR analysis  126 
Total RNA was isolated from 106 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 127 
according to the manufacturer's instructions. Relative gene expression of sirt3, sirt1, superoxide 128 
dismutase 2 (sod2), catalase (cat), mitochondrial NADH dehydrogenase subunit 1 (mtND1), 129 
vascular endothelial growth factor A (vegfa), vascular endothelial growth factor receptor 1 130 
(vegfr1), vimentin and slug were quantified by reverse transcription of total RNA and real time 131 
quantitative PCR (qPCR) analysis as described previously (18). Assays and primers used in this 132 
study are listed in Table 1. Data were analyzed using the 2-ΔΔCt method and presented as the 133 
fold-change in gene expression normalized to endogenous reference gene (β-actin) and relative 134 
to the control. All reactions were carried out in triplicate.  135 
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SDS-PAGE and western blot analysis 136 
For western blot analysis, proteins were isolated using TRIzol reagent (Invitrogen, Carlsbad, 137 
CA, USA) according to the manufacturer's instructions. Protein pellets were dissolved in 1% 138 
SDS in the presence of protease inhibitors (Roche, USA). Total cellular proteins (20 μg per 139 
lane) were resolved by SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad, CA, 140 
USA). Membranes were blocked in 5% nonfat dry milk in TN buffer (50 mM TRIS, 150 mM 141 
NaCl, pH 7.4) for 1 h at 37°C and incubated overnight at 4°C with primary polyclonal or 142 
monoclonal antibodies, followed by incubation with a horseradish peroxidase-conjugated 143 
secondary antibody (Amersham Biosciences Inc., USA) for 1 h at 37°C. Primary and secondary 144 
antibodies used in this study are listed in Table 2. To confirm equal loading and normalize the 145 
bands, AmidoBlack (Sigma Aldrich, St. Louis, MO, USA) was used. The chemiluminescence 146 
signals were detected and analyzed with the Alliance 4.7 Imaging System (UVITEC, 147 
Cambridge, UK).  148 
MTT, growth curves, and CFU assays 149 
For the MTT assay, 7x103 cells were seeded in 96-well plate and 24 h later treated with 150 
hyperoxia. After that, growth medium was removed and 1x MTT was added and cells were 151 
incubated for 4 h in the growth conditions, followed by addition of dimethyl sulfoxide and 20 152 
min incubation with gentle mixing. Absorbance was measured at λ=570 nm on ELISA 153 
microplate reader (LabSystem Multiskan MS, Artisan Technology group, USA). The same 154 
assay was used for determination of cellular growth after seven days of growing in high-glucose 155 
medium in normoxic conditions. For the CFU assay, 2x103 cells were seeded in 5 cm Petri 156 
dishes and 24 h later treated with hyperoxia. After that, the growth medium was replaced with 157 
new one and the cells were incubated for 14 days until the visible colonies were observed. Cells 158 
were fixed with methanol for 10 min, followed by 30 min drying at room temperature. Giemsa 159 
dye was added and incubated for 30 min, washed by reH2O and cells were dried. Colonies were 160 
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counted and the cell viability was determined in comparison with the control cells from 161 
normoxia. 162 
Flow cytometry  163 
Flow cytometry was performed using a Becton-Dickinson FACSCalibur model equipped with 164 
a 488 nm argon laser and a 635 nm red diode laser. Cytoplasmic ROS production was measured 165 
with 2′,7′-dichlorofluorescein diacetate (H2DCFDA, Sigma Aldrich, St. Louis, MO, USA), 166 
mitochondrial superoxide production with MitoSOX Red reagent (ThermoFisher Scientific, 167 
USA), variations in the mitochondrial transmembrane potential (ΔΨm) with 3,3′-168 
dihexyloxacarbocyanine iodide (DiOC(6(3))), Enzo Life Science, SAD), and 10-N-Nonyl 169 
acridine orange (NAO, Invitrogen, Carlsbad, CA, SAD) was used for measurement of 170 
mitochondrial mass. In a 6 well plate, 1,5x105 cells were seeded and 24 h later treated with 171 
hyperoxia. After that, cells were washed with PBS and incubated with specific dye prepared in 172 
the growth medium (40 nM DiOC(6(3))), 50 nM NAO, 5 μM H2DCFDA and 3 μM MitoSOX 173 
Red) for 30 min in the growth conditions. Cells were washed, collected in PBS, and minimum 174 
of 10 000 events were acquired. For discrimination of dead cells, propidium iodide (10 μM) 175 
was used. The collected data were analyzed using FCS Express software version 3.  176 
Determination of mtDNA/nDNA ratio  177 
Total DNA was isolated from MCF-7 cell culture pellets containing 2-5x105 cells, using 178 
AccuPrepR Genomic DNA Extraction Kit (Bioneer, Inc., USA), following the manufacturer's 179 
protocol. DNA samples were fragmented to approximately 1000 bp in size by using Bioruptor® 180 
sonication system (Diagenode, Liège, Belgium). Mitochondrial DNA (mtDNA) copy number 181 
was determined by qPCR of the mitochondrial mtND1 gene relative to the nuclear β-actin 182 
housekeeping gene (Taqman® Gene Expression Assays, Applied Biosystems, UK; nDNA). The 183 
standard mode thermal cycling conditions were used on ABI PRISM Sequence Analyzer 7300 184 
(Applied Biosystems, UK). All experiments were repeated in at least three independent 185 
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biological replicates. MtDNA copy number was determined for each sample using 186 
mtDNA/nDNA ratio. Average CT values were calculated from technical replicates for both 187 
mtDNA and nDNA. Relative mtDNA content was calculated as described previously (19), 188 
using the formula: 2 x 2 (ΔCT), where ΔCT equaled the difference between β-actin gene and 189 
mtnd1 gene CT values (nDNA CT – mtDNA CT). 190 
Mitochondrial oxygen consumption  191 
Oxygen consumption by the cells (107 cells from each clone in respiration buffer: 20 mM 192 
HEPES pH=7.4, 10 mM MgCl2 and 250 mM sucrose dissolved in reH2O) was determined 193 
polarographically by the Clark type electrode (Oxygraph, Hansatech, Norfolk, UK) in an 194 
airtight 1.5 ml chamber at 35°C. After measurement of basal state respiration, the complex III 195 
inhibitor antimycin A (2,5 μM) was added to inhibit the cellular respiration. Oxygen 196 
consumption was calculated in pmol/min/106 cells and normalized to normoxic control group. 197 
Senescence-associated beta-galactosidase (SA-β-gal) activity assay 198 
Cells (4×105 cells per well) were seeded into 24-well plate and 24 h later treated with hyperoxia. 199 
After that, SA-β-gal staining was performed: cells were fixed for 10 min in 1% glutaraldehyde 200 
in DMEM, washed twice with PBS and incubated at 37°C with X-gal (1 mg/mL), dissolved and 201 
incubated for 16 h in a solution containing 40 mM citric acid/Na phosphate buffer pH 6.0, 5 mM 202 
potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl and 2 mM MgCl2. 203 
Senescent cells were evaluated using an Olympus IX50 microscope (Olympus, Japan) under a 204 
×20 lens. Cells were photographed and the percentage of SA-β-gal-positive cells was 205 
calculated. 206 
Statistical analysis 207 
Statistical analysis of data was performed using R v2.15.3 (CRAN) and RStudio for Windows, 208 
v1.1.423 (20). Before all analyses, samples were tested for normality of distribution using 209 
Shapiro-Wilk test. Since all experiments data followed normal distribution, parametric tests for 210 
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multiple comparisons of the samples were performed: two-way ANOVA was used for all 211 
analyses. 212 
Results  213 
Characterization of stable Sirt3 overexpressing MCF-7 clones in normoxia and hyperoxia 214 
Given the fact that breast cancer cell line MCF-7 has reduced expression of Sirt3, which was 215 
shown to act as either tumor suppressor or a tumor promotor in different types of cancer (4), 216 
we have generated stable Sirt3 overexpressing clones to explore its role in this cell model. 217 
Briefly, MCF-7 cells were stably transfected with empty pcDNA3.1+ plasmid or pcDNA3.1+ 218 
plasmid with Flag-tagged Sirt3, and were labelled as MCF-7C or MCF-7S3, respectively. 219 
Stable expression of catalytically active Sirt3 (28kDa) in MCF-7S3 was determined with qPCR 220 
and western blot analysis. qPCR analysis showed 23-fold increase in Sirt3 gene expression level 221 
in MCF-7S3 compared to MCF-7C, and 43-fold increase in hyperoxia (Figure 1A). Western 222 
blot analysis confirmed that the specific signal for Sirt3 protein was absent from MCF-7C, 223 
while MCF-7S3 expressed high levels of Sirt3 equivalent to molecular weight of 28 kDa, as 224 
detected by anti-Sirt3 monoclonal antibody, and this expression was additionally increased 225 
upon hyperoxia (Figure 1B-C). 226 
De novo Sirt3 expression is enriched upon hyperoxia and colocalizes with mitochondria  227 
Next we wanted to determine the expression and localization of Sirt3 protein in MCF-7C and 228 
MCF-7S3 cells. No signal for Sirt3 was detected in MCF-7C, whereas clear signal was observed 229 
in MCF-7S3, and was even stronger upon hyperoxic treatment. These results confirm de novo 230 
expression of Sirt3 protein in MCF-7S3 cells, as expected, in both normoxia and hyperoxia, 231 
with stronger signal per cell in hyperoxia-treated cells (Figure 1D-E). Next, we wanted to 232 
analyze whether Sirt3 might be localized in mitochondria. The confocal microscopy analysis of 233 
Sirt3 (green) and costaining with MitoTracker Deep Red, which specifically dyes mitochondria 234 
(red), revealed overlapping of the two signals (yellow) confirming localization of Sirt3 in 235 
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mitochondria. Also, we found that hyperoxia induced mitochondrial signal intensity in both 236 
clones. These data demonstrate that hyperoxia induced increase in mitochondrial content in 237 
both clones, whereas the Sirt3 expression was increased exclusively in clone with de novo Sirt3 238 
expression.  239 
De novo Sirt3 expression enhances downregulation of pro-angiogenic and cancer-240 
malignancy-related genes and proteins upon hyperoxic treatment 241 
To assess the mechanism by which Sirt3 and hyperoxia influence tumorigenic characteristics 242 
and potential of MCF-7 cells, we surveyed the expression of genes involved in antioxidant 243 
protection (sod2, cat), metabolic regulation (sirt1), mitochondrial electron transfer (mtND1), 244 
angiogenesis (vegfa and vegfr1) and epithelial mesenchymal transition (EMT; vimentin and 245 
slug) (Figure 2A). We found that de novo Sirt3 expression in normoxia downregulated pro-246 
angiogenic gene vegfr1 involved in cell proliferation with having no effect on the expression of 247 
vegfa. In addition, strong downregulation of EMT markers – vimentin and slug, compared to 248 
control clones, was also observed. Hyperoxia induced pro-angiogenic vegfa, vimentin and 249 
mtND1, while having no significant effect on other genes. Interaction of de novo expressed 250 
Sirt3 and hyperoxia downregulated antioxidant defense genes sod2 and cat, along with sirt1. In 251 
addition, slug and vegfr1 were decreased as well. These results collectively demonstrate that 252 
suppressive effect of Sirt3 on pro-angiogenic and cancer-malignancy-related genes in normoxia 253 
is enhanced upon hyperoxic exposure.  254 
Next we wanted to explore if this pattern of regulation was followed by changes in the 255 
expression of proteins involved in these processes. Therefore, we tested the expression of 256 
proteins involved in glycolysis (lactate dehydrogenase A; LdhA), antioxidant defense (Sod2 257 
and Cat), cellular homeostasis (Sirt1), and mitochondrial biogenesis (peroxisome proliferator-258 
activated receptor gamma coactivator 1-alpha; PGC1α) of MCF-7 cells. LdhA, a marker of 259 
aerobic glycolysis, which is considered to be a key enzyme to glycolytic phenotype of tumor 260 
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cells, was downregulated in MCF-7S3 cells. Hyperoxia significantly upregulated LdhA 261 
expression in MCF-7C compared to their normoxic group, while interaction of Sirt3 and 262 
hyperoxia abrogated this effect. Sod2 and Cat showed similar pattern of expression: the 263 
expression was reduced in MCF-7S3 cells, additionally reduced in hyperoxia, and almost 264 
completely absent in hyperoxic MCF-7S3 cells. Hyperoxia lowered Sirt1 level, regardless of 265 
Sirt3 expression. PGC1α expression was markedly increased in MCF-7S3 cells, but reduced in 266 
hyperoxic MCF-7C, whereas interaction of hyperoxia and Sirt3 partially rescued its expression. 267 
Since hyperoxia is known to induce DNA damage, we wanted to check the expression of a 268 
marker of DNA double strand breaks - phosphorylated gamma-H2A histone family, member X 269 
(pγH2AX) and a major tumor suppressor, p53. In normoxic MCF-7C cells the pγH2AX was 270 
absent, whereas the expression of p53 was weak, but slightly increased upon Sirt3 expression. 271 
As expected, hyperoxia induced both pγH2AX and p53, thus showing a clear sign of ROS-272 
induced DNA damage which was even more pronounced upon interaction of Sirt3 and 273 
hyperoxia. These results collectively suggest that Sirt3 and hyperoxia may act in favor of the 274 
inhibiting the proliferation of cancer cells (Figure 2B-I). 275 
De novo Sirt3 expression and hyperoxia decrease proliferation rate and metabolic activity of 276 
MCF-7 cells  277 
Since we found that some of the proliferation and angiogenic factors crucial for tumorigenicity 278 
were downregulated upon de novo expression of Sirt3, we decided to test whether it plays a role 279 
in metabolic activity and proliferative potential (growth curve, clonogenic survival) of MCF-7 280 
cells. The growth curve showed that MCF-7S3 cells grow more slowly than their corresponding 281 
controls (Figure 3A). MTT test showed that MCF-7S3 cells had small, but significantly 282 
decreased metabolic activity (88% of MCF-7C) (Figure 3B). Hyperoxia additionally decreased 283 
metabolic activity in both groups irrespective of Sirt3 expression. The drop in metabolic activity 284 
in normoxic MCF-7S3 was accompanied by decreased capacity to produce colonies, as showed 285 
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with CFU assay (Figure 3C-D). As expected, hyperoxia caused dramatically decreased capacity 286 
to produce colonies in both clones, irrespective of Sirt3 expression. These results collectively 287 
demonstrate the suppressive effect of either Sirt3 or hyperoxia alone on proliferation and 288 
metabolic activity of MCF-7 breast cancer cells.  289 
De novo Sirt3 expression and hyperoxia increase cytosolic and mitochondrial ROS 290 
production  291 
Hyperoxia has a well-known effect of increasing cellular ROS levels. Since Sirt3 is considered 292 
as a fidelity protein that particularly regulates production of mitochondrial ROS (mtROS), we 293 
tested whether de novo expression of Sirt3 would influence mitochondrial or cytosolic ROS 294 
production. By measuring cytosolic ROS production with H2DCFDA fluorescent probe, we 295 
showed that Sirt3 expression increased cytosolic oxidative stress in normoxia (Figure 4A). 296 
Hyperoxia per se increased cytosolic ROS in MCF-7C which was followed by additional 297 
increase in MCF-7S3. Similar pattern was observed for mtROS, i.e. Sirt3 expression and 298 
hyperoxia induced mtROS in both clones (Figure 4B). These results collectively demonstrate 299 
that de novo Sirt3 expression and hyperoxia increase ROS levels in both cytosolic and 300 
mitochondrial compartments.  301 
Hyperoxia-induced alteration of mitochondrial function parameters is associated with de 302 
novo Sirt3 expression 303 
It has been shown that Sirt3-increased mtROS have capacity to induce mtDNA damage, leading 304 
to potential mitochondrial dysfunction (21). Therefore, we wanted to determine whether de 305 
novo Sirt3 expression can influence mtDNA level, along with other mitochondrial parameters, 306 
such as mitochondrial mass, mitochondrial potential and oxygen consumption. First we 307 
examined the ratio of mitochondrial to nuclear DNA in all experimental groups and observed 308 
significant increase in mtDNA level in MCF-7S3 cells, which was also retained in hyperoxic 309 
conditions (Figure 5A). These results demonstrate that in both normoxic and hyperoxic 310 
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conditions Sirt3 overexpression increased relative mtDNA level in respect to nuclear DNA. 311 
Although combination of hyperoxia and Sirt3 elevated mitochondrial mass, and hyperoxia 312 
substantially increased mitochondrial potential regardless of Sirt3 expression (Figure 5B-C), 313 
hyperoxic treatment significantly lowered O2 consumption in both cell lines (Figure 5D).  314 
De novo Sirt3 expression antagonizes senescence  315 
From the above results it is evident that hyperoxia causes DNA damage that eventually results 316 
in cell death. However, we did not observe difference in rate of apoptosis as a result of Sirt3 317 
expression or hyperoxia and Sirt3 (data not shown), thus we conclude that hyperoxia-induced 318 
cell death did not occur via apoptosis. Furthermore, the unchanged expressions of poly (ADP-319 
ribose) polymerase 1 (PARP-1) imply that it also did not occur via PARP-1-dependent cell 320 
death, parthanatos (data not shown). Therefore, we tested whether hyperoxia-induced DNA 321 
damage influenced senescence-associated phenotype in both clones. SA-β-gal activity assay 322 
staining showed that MCF-7S3 cells had lower ratio of SA-β-gal positive cells compared to 323 
MCF-7C cells (Figure 6A-B), whereas hyperoxia induced increase of SA-β-gal positive cells 324 
in both groups. Similar to normoxia, the expression of Sirt3 inhibited hyperoxia-induced 325 
cellular senescence by 20% compared to hyperoxia-treated MCF-7C cells. Rotenone was used 326 
as a positive control for senescence induction (22). 327 
Discussion 328 
In this study we demonstrated the potential of de novo Sirt3 expression to suppress pro-329 
angiogenic and cancer-malignancy-related properties of human MCF-7 breast cancer cells, as 330 
well as to enhance their susceptibility to hyperoxic treatment. Sirt3 has bifunctional role, acting 331 
as both oncogene and tumor suppressor, depending on the tissue and cancer-type specific 332 
metabolic programs (4). Because breast cancer cells have strikingly reduced Sirt3 level, and 333 
20% of them have almost no detectable Sirt3 protein (11), we developed de novo Sirt3 334 
expressing transfectants to examine its effect on characteristics of MCF-7 breast cancer cells, 335 
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combined with hyperoxic treatment which was earlier shown to suppress the growth of certain 336 
mammary carcinoma cells (7). 337 
A number of breast cancer cells, particularly MCF-7, depend on a mixture of glycolysis and 338 
OXPHOS to support their proliferation (23). The faster growth rate of control MCF-7 clones in 339 
high-glucose medium (Figure 3A) implies the preferential use of glycolysis pathway to 340 
facilitate the uptake and incorporation of nutrients into the biomass thus supporting their faster 341 
proliferation (24). It seems that Sirt3 induced the metabolic shift from glycolysis to OXPHOS, 342 
which involves the PGC1α-induced mitochondrial regulation, therefore causing decrease in fast 343 
supply of nutrients usually provided by glycolysis and consequently reduced metabolic activity 344 
and clonogenic capacity of MCF-7 cells in normoxic conditions. Besides increasing PGC1α, a 345 
master regulator of mitochondrial biogenesis, i.e. oxidative metabolism (25), Sirt3 also reduced 346 
expression of LdhA, a marker of glycolysis and proliferating cells, thus confirming previous 347 
reports indicating that metabolic reprogramming mediated by Sirt3 contributes to its tumor-348 
suppressive role in human breast cancer cell lines (11).   349 
Sirt3 reduced vegfr1 and two markers of EMT, vimentin and slug. Since vimentin contributes 350 
to cell polarity and motility and regulates the expression of slug to further enhance EMT 351 
phenotypes and cancer malignancy (26), the dramatic reduction of these genes suggests that 352 
Sirt3 indeed acts as a suppressor of EMT transition and malignant properties of the MCF-7 353 
cells. In addition, Sirt3 reduced senescence of MCF-7 cells. Although senescence is usually 354 
activated in a variety of premalignant steps to limit tumor progression (27), in certain contexts 355 
it may create a pro-oncogenic tissue environment, thus leading to functional decline of tissues 356 
and the rise in cancer incidence (28). Therefore, reduced senescence of MCF-7 cells may also 357 
contribute to the role of Sirt3 in inhibiting their tumorigenic properties.Another crucial tumor 358 
suppressor, p53, is often mutated or deregulated in many human cancers (29). Since cells 359 
without a functional p53 lack the DNA-damage-sensing capability to induce the protective 360 
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response (30), its slight increase upon the Sirt3 expression may have beneficial effect on 361 
suppression of tumorigenic potential. Taking all these factors in consideration, we conclude 362 
that Sirt3 inhibits the tumorigenic properties of MCF-7 cells in normoxia.  363 
Although tumor cells often live in hypoxic conditions due to metabolic and structural 364 
abnormalities, their angiogenesis, growth and survival depend upon the sufficient supply of 365 
oxygen. The high ROS production and pro-angiogenic gene expression upon hyperoxic 366 
treatment at first suggest tumor-promoting effects of hyperoxia, since  cells respond to elevated 367 
ROS levels by increasing the vegfa expression through the activation of signaling pathways 368 
usually involved in tumorigenesis (31). Hyperoxia also significantly upregulated the EMT 369 
marker vimentin, as well as LdhA, an indicator of  lactate generation, which initiates the vegf 370 
production (32) and contributes to aerobic glycolysis. This is also supported by a recent study 371 
showing higher uptake of glucose in the hyperoxia-treated MCF-7 cells (33). However, 372 
hyperoxia initiated a number of events indicative of suppressing the tumorigenic properties, 373 
e.g. strong activation of p53, induction of senescence and mitochondrial dysfunction, as well 374 
as depleted PGC1α, Sirt1 and Sod2 proteins abundance, which may finally be responsible for 375 
diminished cell proliferation and survival, as shown recently (12, 37). Moreover, hyperoxia 376 
increased mitochondrial potential and ROS production. Since even slight increase in 377 
mitochondrial potential may cause significant rise in ROS levels (38), this finding implies that 378 
tumor-suppressive effect of hyperoxia may be partially achieved through mitochondrial 379 
dysfunction. Excessive ROS are also important for establishing cellular senescence (34), which 380 
usually suppresses tumors in response to stress and is highly dependent on functional p53 (30). 381 
Although one would expected that cells with a lot of DNA damage would undergo apoptosis 382 
pathway, MCF-7 cells rather become senescent than enter the apoptosis, probably due to the 383 
lack of functional caspase 3 expression (35). This was also presented in previous studies 384 
showing that hyperbaric oxygen treatment lowers proliferation, but does not induce apoptosis 385 
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in MCF-7 cells (36). Collectively and in agreement with previous studies (39, 36), these results 386 
show that hyperoxia inhibits proliferation and survival of cancer cells through the mitochondrial 387 
dysfunction and activation of p53 upon DNA damage and induction of senescence.  388 
Under hyperoxic conditions, Sirt3 additionally downregulated majority of genes involved in 389 
angiogenesis and tumor promotion, as well as EMT-inducing gene slug. Furthermore, increased 390 
DNA damage was accompanied with additional increase of ROS levels and consequent 391 
mitochondrial dysfunction and depletion of antioxidative enzymes. Sirt3 also antagonized 392 
senescence in both conditions, as expected (40).  393 
The mitigation of tumorigenic properties and enhancement of the susceptibility of the MCF-7 394 
breast cancer cells to the hyperoxic treatment upon the de novo Sirt3 expression, observed 395 
through their reduced survival, proliferation and mitochondrial function, as well as upregulation 396 
of the cells growth suppressors, indicates that both Sirt3 and hyperoxia, especially combined, 397 
have a potential to negatively modulate the properties of the cancer cells and that they should 398 
be further explored, in vitro and particularly in vivo, as an adjuvant tumor therapy in breast 399 
cancer malignancies. 400 
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Tables 514 
Table 1. Assays and primers used for real time quantitative PCR analyses 515 
Gene Assay IDa/primersb Product size (bp) 
β-actin Hs01060665_g1 63 
mtND1 Hs02596873_s1 143 
sod2 Hs01553554_m1 69 
cat Hs00156308_m1 68 
sirt1 Hs01009005_m1 94 
sirt3 Hs00953477_m1 83 
vegfa Hs00900058_m1 81 
vegfr1 Hs01052936_m1   72 
vimentin 
5′-CGTGATGCTGAGAAGTTTCGTTGA -3′ 
5′-CCAAACTTTTCCTCCCTGAACC-3 
142 
slug 
5′-GAGGAGAAAATGCCTTTG -3′ 
5′-ATGAGCAATCTGGCTGCT -3′ 
119 
a Taqman
®
 Applied Biosystems, UK 516 
b Power SYBR™ Green PCR Master Mix, AppliedBiosystems, UK 517 
  518 
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Table 2. Primary and secondary antibodies used for Western blot analyses 519 
Primary antibody Dilution Manufacturer 
anti-Sirt3 1:400 Cell Signaling Technology, USA 
anti-LdhA 1:200 Santa Cruz Biotehnology, USA 
anti-Sod2 1:2000 Abcam, UK 
anti-Sirt1 1:300 Santa Cruz Biotehnology, USA 
anti-PGC1α 1:1000 Novus Biologicals, USA 
anti-Cat 1:500 Abcam, UK 
anti-gammaH2AX 1:2000 Abcam, UK 
anti-p53 (DO-1) 1:2000 Santa Cruz Biotehnology, USA 
Secondary antibody  
anti- rabbit IgG HRP linked 1:4000 GE Healthcare, UK 
anti-mouse IgG HRP linked 1:2000 Santa Cruz Biotehnology, USA 
 520 
  521 
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Figure captions 522 
Figure 1. Characterization of MCF-7C and MCF-7S3 cells. 523 
(1A) Real-time qPCR analysis of sirt3 gene expression level in MCF-7C and MCF-7S3 cells in 524 
normoxia and hyperoxia. Significant effect of sirt3 (ap<0.001) and hyperoxia (bp<0.001) is 525 
observed, as well as the effect of their interaction (p=0.015). The results are presented as fold-526 
change ± S.E., and normalized to control group. The fold-change in gene expression was 527 
calculated using the 2-ΔΔCT method. β-actin was used as the endogenous control. Experiments 528 
were repeated at least three times and representative data are shown. (1B) Densitometry analysis 529 
of Sirt3 protein expression level in MCF-7C and MCF-7S3 cells in normoxia and hyperoxia. 530 
Data are presented as mean ± S.D. Significant effect of Sirt3 (ap<0.001) and hyperoxia 531 
(bp<0.01) is observed, as well as the effect of their interaction (p=0.008). (1C) Immunoblots of 532 
Sirt3 protein expression level. Amidoblack was used as a loading control. The experiments 533 
were repeated at least three times and representative blots are shown. (1D, E) Sirt3 colocalizes 534 
with mitochondria and is enriched upon hyperoxia. Confocal image analysis of MCF-7 clones 535 
in normoxia and hyperoxia. Representative confocal image analysis of Sirt3 localization (green) 536 
in normoxia and hyperoxia. Mitochondria and nuclei were detected with Mitotracker Deep Red 537 
or DAPI, respectively. Overlay image shows complete overlap (Yellow) of two staining 538 
patterns: fluorescence from the Sirt3–FITC protein (Green) and fluorescence from the 539 
Mitotracker Deep Red stained mitochondria (Red).  540 
Figure 2. De novo Sirt3 expression enhances downregulation of pro-angiogenic and cancer-541 
malignancy-related genes and proteins upon hyperoxia 542 
(2A) Heatmap of differential gene expression as determined using real-time quantitative PCR 543 
method. The fold-change in gene expression was calculated using the 2-ΔΔCT method and β-actin 544 
as the endogenous control. Color of the squares on the heatmap corresponds to the mean value 545 
of the log fold-change from three biological and three technical replicates. β-actin was used for 546 
25 
 
normalization. Significant effect of sirt3 was found for vegfr1 – fold-change: -2.0, p<0.05; 547 
vimentin – fold-change: -4.76, p<0.001; slug – fold-change: -2.70, p<0.05. Significant effect of 548 
hyperoxia was found for: vegfa – fold-change: +2.0, p<0.05; vimentin – fold-change: +2.17, 549 
p<0.01; mtND1 – fold-change: +2.0, p<0.05. Significant effect of interaction of sirt3 and 550 
hyperoxia was found for: vegfr1 – fold-change: -2.43, p<0.05; slug – fold-change: -3.84, 551 
p<0.01; sirt1 – fold-change: -2.38, p<0.05; sod2 – fold-change: -4.34, p<0.001; cat – fold-552 
change: -2.94, p<0.01. (2B) Protein expression levels of Sirt1, PGC1α, Cat, p53, LdhA, Sod2 553 
and pγH2AX. Amidoblack was used as a loading control. The experiments were repeated three 554 
times and representative immunoblots are shown. (2C-I) Graphical analysis of immunoblots of 555 
protein expression. (2C) For Sirt1 there was significant effect of sirt3 (ap<0.001) and hyperoxia 556 
(bp<0.001). (2D) For PGC1α there was significant effect of sirt3 (ap<0.001) and hyperoxia 557 
(bp<0.001), as well as of their interaction (p<0.001). (2E) For Cat there was significant effect 558 
of sirt3 (ap<0.001) and hyperoxia (bp<0.001), as well as of their interaction (p<0.001). (2F) For 559 
p53 there was significant effect of sirt3 (ap<0.001) and hyperoxia (bp<0.001). (2G) For LdhA 560 
there was significant effect of sirt3 (ap<0.001), hyperoxia (bp<0.05) and their interaction 561 
(p=0.015). (2H) For Sod2 there was significant effect of sirt3 (ap<0.01) and hyperoxia 562 
(bp<0.001). (2I) For γH2Ax there was significant effect of sirt3 ap<0.001, hyperoxia (bp<0.001) 563 
and their interaction (p<0.001). 564 
Figure 3. De novo Sirt3 expression and hyperoxia result in decrease of metabolic activity and 565 
survival.  566 
(3A) Growth curves of MCF-7C and MCF-7S3 clones in high-glucose medium in normoxia. 567 
The representative experiment is shown. Results are presented as mean ± S.D. ***p<0.001, 568 
MCF-7C vs. MCF-7S3. (3B) Percentage of metabolic activity of MCF-7S3 cells in normoxia 569 
and hyperoxia compared to MCF-7C cells. Significant effect of Sirt3 (ap<0.001) and hyperoxia 570 
(bp<0.001) on metabolic activity is observed. Results are shown as mean ± S.D. (3C) Graphical 571 
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display of number of colonies (CFU assay) relative to normoxic MCF-7C. Significant effect of 572 
Sirt3 (ap<0.005) and hyperoxia (bp<0.001) on cellular clonogenic capacity is observed. The 573 
experiments were repeated at least three times. (3D) Representative plates stained with crystal 574 
violet.  575 
Figure 4. De novo Sirt3 expression and hyperoxia increase cytosolic and mitochondrial ROS 576 
production.  577 
(4A) Cytosolic ROS levels were examined by H2DCFDA staining. Results are presented as 578 
mean ± S.D. The experiments were performed at least three times and representative data are 579 
shown. Significant effect of Sirt3 (ap<0.001) and hyperoxia (bp<0.001), and their interaction on 580 
cytosolic ROS production is observed (p<0.01). (4B) mtROS levels were measured with 581 
MitoSOX Red. Mean fluorescence intensity was compared to normoxic control clone. 582 
Significant effect of Sirt3 (ap<0.001) and hyperoxia (bp<0.001), and their interaction on 583 
mitochondrial ROS production is observed (p=0.01).  584 
Figure 5. Hyperoxia-induced alteration in mitochondrial function parameters is associated 585 
with de novo Sirt3 expression 586 
(5A) mtDNA content of MCF-7C and MCF-7S3 in normoxia and hyperoxia. Significant effect 587 
of Sirt3 (ap<0.001) and the interaction of Sirt3 and hyperoxia (p<0.05) on mtDNA content is 588 
observed. (5B) Significant effect of Sirt3 (ap<0.05) and hyperoxia (bp<0.001) on mitochondrial 589 
potential is observed. (5C) Significant effect of Sirt3 (ap<0.001), hyperoxia (bp<0.001) and their 590 
interaction (p<0.05) on mitochondrial mass is observed. Mean fluorescence intensity of all 591 
experimental groups was compared to normoxic control clone. (5D) Significant effect of 592 
hyperoxia (bp<0.001) on oxygen consumption is observed. Data are presented as percent of 593 
mean ± S.D. The experiments were performed at least three times and representative data are 594 
shown.   595 
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Figure 6. De novo Sirt3 expression antagonizes senescence in both normoxia and hyperoxia 596 
(6A) Graphical display of the ratio of β-gal positive cells in normoxic and hyperoxic conditions. 597 
Data present percentage of positive senescent cells analyzed by β-galactosidase staining. The 598 
experiments were repeated three times and representative data are shown. Significant effect of 599 
Sirt3 (ap<0.001), hyperoxia (bp<0.001) and their interaction (p<0.01) on senescence-associated 600 
β-galactosidase activity is observed. (6B) Representative images of cells stained for 601 
senescence-associated β-galactosidase activity. Rotenone was used as a positive control for 602 
senescence induction.  603 
